deltatrials
Completed NA INTERVENTIONAL 2-arm NCT01180985

Dispensing Evaluation of a Galyfilcon A Prototype Lens and a Marketed Contact Lens

Sponsor: Johnson & Johnson Vision Care, Inc.

Conditions Myopia
Updated 8 times since 2017 Last updated: Jun 18, 2018 Started: Jun 1, 2010 Primary completion: Jul 1, 2010 Completion: Jul 1, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01180985, this NA trial focuses on Myopia and remains completed. Sponsored by Johnson & Johnson Vision Care, Inc., it has been updated 8 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshotCompleted~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotCompleted~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshotCompleted~Jul 2018 – ~Jan 2021 · 30 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

8 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jul 2018 — Jan 2021 [monthly]

    Completed NA

  5. Jun 2018 — Jul 2018 [monthly]

    Completed NA

Show 3 earlier versions
  1. Oct 2017 — Jun 2018 [monthly]

    Completed NA

  2. Feb 2017 — Oct 2017 [monthly]

    Completed NA

  3. Jan 2017 — Feb 2017 [monthly]

    Completed NA

    First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Johnson & Johnson Vision Care, Inc.
Data source: Johnson & Johnson Vision Care, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .